Literature DB >> 9378983

Cytokines promote glomerular mesangial cell survival in vitro by stimulus-dependent inhibition of apoptosis.

A Mooney1, T Jobson, R Bacon, M Kitamura, J Savill.   

Abstract

Resolution of glomerular inflammation requires the removal of proliferating resident glomerular mesangial cells, but excessive loss of glomerular cells is a feature of postinflammatory scarring. Because apoptosis regulates mesangial cell number in glomerular inflammation, we have studied the exogenous control of apoptosis triggered in cultured mesangial cells by stimuli likely to be important in vivo. Apoptosis could be induced by serum deprivation to model decreased availability of survival factors, by etoposide as an example of DNA-damaging agents, by ligation of mesangial cell Fas, and by protein synthesis inhibition by cycloheximide. Insulin-like growth factor I (IGF-I), IGF-II, and basic fibroblast growth factor were each able to suppress apoptosis induced by serum deprivation, whereas TGF-beta 1, epidermal growth factor, and platelet-derived growth factor had no effect. IGF-I and IGF-II (but not basic fibroblast growth factor) were also able to protect cells from apoptosis induced by etoposide or cycloheximide. However, Fas-mediated apoptosis was resistant to suppression by all three cytokines. None of the cytokines tested caused a change in the levels of expression of Bcl-2, Bax, Bcl-x, or Bak proteins. The survival-promoting properties of serum-free medium conditioned by mesangial cells was abrogated by neutralizing IGF-I Ab. These experiments are the first to define cytokines that inhibit apoptosis and thereby promote survival of mesangial cells, and the data indicate a paracrine survival signaling role for IGF-I. Finally, the data show that Fas ligation can override cytokine survival signaling, emphasizing a candidate role for this molecule in the undesirable apoptotic loss of mesangial cells during the progression of glomerular scarring.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9378983

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Apoptosis and myofibroblasts in the pathogenesis of systemic sclerosis.

Authors:  Eugene Kissin; Joseph H Korn
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

2.  Apoptosis of endothelial cells is associated with paracrine induction of adhesion molecules: evidence for an interleukin-1beta-dependent paracrine loop.

Authors:  M J Hébert; S R Gullans; H S Mackenzie; H R Brady
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

Review 3.  Cardiometabolic syndrome and chronic kidney disease.

Authors:  Guido Lastra; Camila Manrique; Samy I McFarlane; James R Sowers
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

4.  Type IV collagen and laminin regulate glomerular mesangial cell susceptibility to apoptosis via beta(1) integrin-mediated survival signals.

Authors:  A Mooney; K Jackson; R Bacon; C Streuli; G Edwards; J Bassuk; J Savill
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

5.  Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation.

Authors:  N Trim; S Morgan; M Evans; R Issa; D Fine; S Afford; B Wilkins; J Iredale
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

6.  Regulation of proliferation of human colonic subepithelial myofibroblasts by mediators important in intestinal inflammation.

Authors:  T M Jobson; C K Billington; I P Hall
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

7.  The potential renal toxicity of silver nanoparticles after repeated oral exposure and its underlying mechanisms.

Authors:  Hamed Nosrati; Manijeh Hamzepoor; Maryam Sohrabi; Massoud Saidijam; Mohammad Javad Assari; Nooshin Shabab; Zahra Gholami Mahmoudian; Zohreh Alizadeh
Journal:  BMC Nephrol       Date:  2021-06-18       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.